Age-Related Macular Degeneration – AMD
Age-Related Macular Degeneration (AMD) is characterized by pathological changes of the retinal pigment epithelium (RPE), progressive degeneration of photoreceptors, thickened Bruch’s membrane and choroidal neovascularizatin. These alterations lead to the loss of sharp, central vision. It is an age-related process and usually develops after a person reaches 50 years.
In Western Europe and USA 30% of people older than 75 years suffer from different types of AMD. 85-90% cases of AMD are dry AMD, which have no treatment. 10-15% cases of AMD are wet AMD, which have number of treatments available (injection into the eye to stop further development) and early diagnosis can save vision.
The genetic test developed by Asper Biotech is based on the evaluation of single nucleotide polymorphisms (SNPs) in genes associated with AMD. The AMD risk assessment test enables analysis of 3 SNPs in genes CFH and ARMS2 that have been associated with higher risk for disease-onset. The test also enables to detect 3 SNPs in genes CFB and C2 that are associated with reduced risk of disease.
Genetic test is recommended for patients with known cases of AMD in the family and close relatives of patients with increased risk. AMD increased risk assessment enables prevention and early diagnosis of the disease. Early diagnosis is vital to delay progression of disease and vision loss. The test is available with diagnostic package service (includes DNA extraction, genotyping, interpretation, hard copy of the results report).
ORDERING
Age-Related Macular Degeneration – read more
Age-Related Macular Degeneration (AMD) is characterized by pathological changes of the retinal pigment epithelium (RPE), progressive degeneration of photoreceptors, thickened Bruch’s membrane and choroidal neovascularizatin. These alterations lead to the loss of sharp, central vision. It is an age-related process and usually develops after a person reaches 50 years.
In Western Europe and USA 30% of people older than 75 years suffer from different types of AMD. 85-90% cases of AMD are dry AMD, which have no treatment. 10-15% cases of AMD are wet AMD, which have number of treatments available (injection into the eye to stop further development) and early diagnosis can save vision.
The test developed by Asper Biotech is based on the evaluation of single nucleotide polymorphisms (SNPs) in genes associated with AMD. The AMD risk assessment test enables analysis of 3 SNPs in genes CFH and ARMS2 that have been associated with higher risk for disease-onset. The test also enables to detect 3 SNPs in genes CFB and C2 that are associated with reduced risk of disease.
Test is recommended for patients with known cases of AMD in the family and close relatives of patients with increased risk. AMD increased risk assessment enables prevention and early diagnosis of the disease. Early diagnosis is vital to delay progression of disease and vision loss.
|
